Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1669
    +0.0017 (+0.15%)
     

  • GBP/USD

    1.2584
    +0.0037 (+0.30%)
     

  • Bitcoin GBP

    50,826.21
    +24.32 (+0.05%)
     

  • CMC Crypto 200

    1,378.35
    +65.72 (+5.00%)
     

  • S&P 500

    5,160.61
    +32.82 (+0.64%)
     

  • DOW

    38,801.06
    +125.38 (+0.32%)
     

  • CRUDE OIL

    78.79
    +0.68 (+0.87%)
     

  • GOLD FUTURES

    2,333.70
    +25.10 (+1.09%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • HANG SENG

    18,578.30
    +102.38 (+0.55%)
     

  • DAX

    18,159.76
    +158.16 (+0.88%)
     

  • CAC 40

    7,994.72
    +37.15 (+0.47%)
     

Personalis to Announce First Quarter 2024 Financial Results

Business Wire
·1-min read

FREMONT, Calif., April 24, 2024--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the call by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424251573/en/

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com